LOAd-703 is under clinical development by Lokon Pharma and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LOAd-703’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LOAd-703 overview
LOAd-703 is under development for the treatment of pancreatic cancer including pancreatic ductal adenocarcinoma, gallbladder cancer, biliary cancer, colorectal cancer, fallopian tube cancer, epithelial ovarian cancer, primary peritoneal cancer, colorectal carcinoma (CRC), pancreatic carcinoma (PC), biliary cancer, epithelial ovarian carcinoma, metastatic melanoma. It is administered through intratumoral route as a suspension and it is an oncolytic adenovirus consist of serotype 5 from serotype 35 (Ad5/35) which is modified to express CD40 ligand (CD40L) and 4-1BBL. It was also under development for carcinomas and B-cell lymphoma.
Lokon Pharma overview
Lokon Pharma, a subsidiary of Nexttobe AB, is a biotech company in the forefront of developing immuno stimulatory gene therapy for cancer based on oncolytic viruses, gene engineering, solid expertise in cancer biology and immunology. The company is headquartered in Uppsala, Stockholm, Sweden.
For a complete picture of LOAd-703’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
